Skip to main content
. 2019 Mar 30;11(4):455. doi: 10.3390/cancers11040455

Figure 6.

Figure 6

CXCR7 expression in different NSCLC cell lines with or without gefitinib treatment and CXCR7 expression in NSCLC patients. (a) Western blot analysis of H1299, H1650 EGFRwt/wt, and EGFR−/− cells. (b) Western blot analysis of H1299, H1650, and HCC827 cells treated with different doses of gefitinib over time. (c) Immunohistochemical staining of CXCR7 in NSCLC primary tumor samples (n = 47). The blue and black arrows show the expression of CXCR7 in mature and less differentiated squamous cell lung carcinoma (SQCC), respectively.